NCT05708755 CMV Immunity Monitoring in Lung Transplant Recipients
| NCT ID | NCT05708755 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | NYU Langone Health |
| Condition | Lung Transplant; Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-09-13 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 50 participants in total. It began in 2024-09-13 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.
Eligibility Criteria
Inclusion Criteria: 1. Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health 2. Pre-existing serological immunity to CMV (R+) 3. Able and willing to provide informed consent Exclusion Criteria: 1. Anti-thymocyte globulin induction immunosuppression 2. Perioperative desensitization 3. Pregnant or breastfeeding women
Contact & Investigator
Luis Angel, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT05708755 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Lung Transplant; Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05708755 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05708755 currently recruiting?
Yes, NCT05708755 is actively recruiting participants. Contact the research team at Tyler.lewis@nyulangone.org for enrollment information.
Where is the NCT05708755 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05708755 clinical trial?
NCT05708755 is sponsored by NYU Langone Health. The principal investigator is Luis Angel, MD at NYU Langone Health. The trial plans to enroll 50 participants.